HOLLY REED: Open Payments
NPI 1588107031 · BEMUS POINT, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$441 in 22 payments from 11 companies in 2025. Trend: 2023 $321 · 2024 $401 · 2025 $441
Food & beverage: $441
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 7 | $145 |
| GlaxoSmithKline, LLC. | 3 | $53 |
| AstraZeneca Pharmaceuticals LP | 2 | $43 |
| Lilly USA, LLC | 2 | $42 |
| Paratek Pharmaceuticals, Inc. | 2 | $36 |
| ALK-Abello, Inc | 1 | $26 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Boston Scientific Corporation | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Seqirus USA Inc | 1 | $17 |
Products named: TRELEGY ELLIPTA, FARXIGA, NUZYRA, Odactra, VOQUEZNA, JARDIANCE, Wegovy, WATCHMAN FLX.
Industry payments across NY — which companies pay providers there.
